




ALTERNATIVE TO PTO/SB/08 a/b (07-05)

Substitute for form 1449/PTO			Complete if Known		
			Application Number	09/802,376	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Filing Date	March 9, 2001	
			First Named Inventor	Gary VAN NEST	
			Art Unit	1635	
			Examiner Name	J. Zara	
Sheet	1	of	3	Attorney Docket Number	377882001700


U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
JZ	1.	US-2001/0046967-A1	11-29-2001	Van Nest	
	2.	US-2003/0022852-A1	01-30-2003	Nest et al.	
	3.	US-2003/0059773-A1	03-27-2003	Van Nest et al.	
	4.	US-2003/0129251-A1	07-10-2003	Van Nest et al.	
	5.	US-2003/0133988-A1	07-17-2003	Fearon et al.	
	6.	US-2003/0175731-A1	09-18-2003	Fearon et al.	
	7.	US-2003/0199466-A1	10-23-2003	Fearon et al.	
	8.	US-2003/0216340-A1	11-20-2003	Van Nest et al.	
	9.	US-2005/0037403-A1	02-17-2005	Krieg et al.	
	10.	US-5,770,434-A	06-23-1998	Huse	
	11.	US-6,086,901-A	07-11-2000	O'Hagan et al.	
	12.	US-6,194,388-B1	02-27-2001	Krieg et al.	
	13.	US-6,207,646-B1	03-27-2001	Krieg et al.	
	14.	US-6,214,806-B1	04-10-2001	Krieg et al.	
	15.	US-6,239,116-B1	05-29-2001	Krieg et al.	
	16.	US-6,306,405-B1	10-23-2001	O'Hagan et al.	
	17.	US-6,458,370-B1	10-01-2002	O'Hagan et al.	
	18.	US-6,534,062-B2	03-18-2003	Raz et al.	
	19.	US-6,544,518-B1	04-08-2003	Friede et al.	
	20.	US-6,558,670-B1	05-06-2003	Friede et al.	
	21.	US-6,610,661-B1	08-26-2003	Carson et al.	
	22.	US-6,855,492-B2	02-15-2005	O'Hagan et al.	
	23.	US-6,884,435-B1	04-26-2005	O'Hagan et al.	


FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁵
		Country Code ² -Number ³ -Kind Code ⁴ (if known)	MM-DD-YYYY			
JZ ↓	24.	WO-00/54803-A2,A3	09-21-2000	Panacea Pharmaceuticals, LLC		
	25.	WO-00/61161-A2,A3	10-19-2000	University of Madras		
	26.	WO-01/22972-A2,A3	04-05-2001	University of Iowa Research Foundation et al.		
	27.	WO-01/22990-A2,A3	04-05-2001	Coley Pharmaceutical Group, Inc. et. al.		
	28.	WO-01/35991-A2,A3	05-25-2001	Dynavax Technologies Corporation		
	29.	WO-01/51500-A1	07-19-2001	The United States of America, represented by The Secretary, Department of Health and Human Services		
	30.	WO-01/54720-A1	08-02-2001	Cistem Biotechnologies GMBH		
	31.	WO-03/015816-A1	02-27-2003	Dynavax Technologies Corporation		

Examiner Signature		Date Considered	4-26-06
pa- 1058851			

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	09/802,376
				Filing Date	March 9, 2001
				First Named Inventor	Gary VAN NEST
				Art Unit	1635
				Examiner Name	J. Zara
Sheet	2	of	3	Attorney Docket Number	377882001700

*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials [*]	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	32.	Aderem, A. et al. (December 22, 2000). "How do you see CG?" <i>Cell</i> 103:993-996.	
	33.	Fearon, K. et al. (2003). "A Minimal Human Immunostimulatory CpG Motif That Potently Induces IFN- γ and IFN- α Production," <i>Eur. J. Immunol.</i> 33:2114-2122.	
	34.	Gursel, I. et al. (2001). "Sterically Stabilized Cationic Liposomes Improve the Uptake and Immunostimulatory Activity of CpG Oligonucleotides," <i>J. Immunology</i> 167:3324-3328.	
	35.	International Search Report mailed on February 11, 2002 for PCT Application No. PCT/US01/07848 filed on March 12, 2001, three pages.	
	36.	International Search Report mailed on August 27, 2002 for PCT Application No. PCT/US01/25364 filed on August 13, 2001, four pages.	
	37.	International Search Report mailed on February 11, 2002 for PCT Application No. PCT/US01/07843 filed on March 12, 2001, three pages.	
	38.	Kandimalla, E.R. et al. (2001). "Effect of Chemical Modifications of Cytosine and Guanine in a CpG-Motif of Oligonucleotides: Structure-Immunostimulatory Activity Relationships," <i>Bioorg. Med. Chem.</i> 9:807-813.	
	39.	Kato, D. et al. (2003). "The Design of Polymer Microcarrier Surfaces for Enhanced Cell Growth," <i>Biomaterials</i> 24:4253-4264.	
	40.	Kazzaz, J. et al. (2000). "Novel Anionic Microparticles are a Potent Adjuvant for the Induction of Cytotoxic T Lymphocytes Against Recombinant p55 gag From HIV-1," <i>J. Controlled Release</i> 67:347-356.	
	41.	Klinman, D.M. et al. (2004). "Use of CpG Oligodeoxynucleotides as Immune Adjuvants," <i>Immunological Reviews</i> 199:201-216.	
	42.	Kofler, N. et al. (1996). "Preparation and Characterization of Poly-(D,L-lactide-co-glycolide) and Poly-(L-lactic acid) Microspheres with Entrapped Pneumotropic Bacterial Antigens," <i>J. Immunological Methods</i> 192:25-35.	
	43.	Krieg, A.M. (2002). "CpG Motifs in Bacterial DNA and Their Immune Effects," <i>Annual Review Immunology</i> 20:709-760.	
	44.	Lefeber, D.J. et al. (December 2003). "Th1-Directing Adjuvants Increase the Immunogenicity of Oligosaccharide-protein Conjugate Vaccines Related to <i>Streptococcus pneumoniae</i> Type 3," <i>Infection and Immunity</i> 71(12):6915-6920.	
	45.	Maloy, K.J. et al. (1994). "Induction of Mucosal and Systemic Immune Responses by Immunization with Ovalbumin Entrapped in Poly(lactide-co-glycolide) Microparticles," <i>Immunology</i> 81:661-667.	
	46.	Nellore, R.V. et al. (September-October 1992). "Evaluation of Biodegradable Microspheres as Vaccine Adjuvant for Hepatitis B Surface Antigen," <i>J. Parenteral Science and Technology</i> 46(5):176-180.	
	47.	O'Hagan, D.T. et al. (2000). "Microparticles in MF59, a Potent Adjuvant Combination for a Recombinant Protein Vaccine Against HIV-1," <i>Vaccine</i> 18:1793-1801.	
	48.	O'Hagan, D.T. et al. (2001). "Recent Developments in Adjuvants for Vaccines Against Infectious Diseases," <i>Biomolecular Engineering</i> 18:69-85.	
	49.	O'Hagan, D.T. et al. (2002). "Synergistic Adjuvant Activity of Immunostimulatory DNA and Oil/Water Emulsions for Immunization with HIV p55 gag Antigen," <i>Vaccine</i> 20:3389-3398.	

Examiner Signature		Date Considered	4-26-06
--------------------	---	-----------------	---------

pa- 1058851

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete if Known		
			Application Number	09/802,376	
			Filing Date	March 9, 2001	
			First Named Inventor	Gary VAN NEST	
			Art Unit	1635	
			Examiner Name	J. Zara	
Sheet	3	of	3	Attorney Docket Number	377882001700


83	50.	Plenat, F. (June 1996). "Animal Models of Antisense Oligonucleotides: Lessons for Use in Humans," <i>Molecular Medicine Today</i> 2(6):250-257.	
	51.	Ponchel, G. et al. (1998). "Specific and Non-specific Bioadhesive Particulate Systems for Oral Delivery to the Gastrointestinal Tract," <i>Advanced Drug Delivery Reviews</i> 34:191-219.	
	52.	Ryan, E.J. et al. (August 2001). "Immunomodulators and Delivery Systems for Vaccination by Mucosal Routes," <i>Trends in Biotechnology</i> 19(8):293-304.	
	53.	Singh, M. et al. (November 1999). "Advances in Vaccine Adjuvants," <i>Nature Biotechnology</i> 17:1075-1081.	
	54.	Singh, M. et al. (January 18, 2000). "Cationic Microparticles: A Potent Delivery System for DNA Vaccines," <i>PNAS</i> 97(2):811-816.	
	55.	Uhlmann, E. et al. (2003). "Recent Advances in the Development of Immunostimulatory Oligonucleotides," <i>Current Opinion in Drug Discovery and Development</i> 6(2):204-217.	
	56.	Van Uden, J. et al. (November 1999). "Immunostimulatory DNA and Applications to Allergic Disease," <i>Journal of Allergy and Clinical Immunology</i> 104(5):902-910.	
	57.	Verthelyi, D. et al. (February 15, 2001). "Human Peripheral Blood Cells Differentially Recognize and Respond to Two Distinct CpG Motifs," <i>J. Immunol.</i> 166(4):2372-2377.	
↓	58.	Weeratna, R.D. et al. (2000). "CpG DNA Induces Stronger Immune Responses with less Toxicity than Other Adjuvants," <i>Vaccine</i> 18:1755-1762.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*Applicant's unique citation designation number (optional). *Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	g 3 -	Date Considered	4/26/06
--------------------	-------	-----------------	---------

pa- 1058851

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>				Docket Number 377882001700		Application Number 09/802,376	
				Applicant Gary VAN NEST and Stephen TUCK			
				Filing Date March 9, 2001		Group Art Unit 1635	
				Mailing Date November 2, 2004			
U.S. PATENT DOCUMENTS							
Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
FOREIGN PATENT DOCUMENTS							
Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO
93	1.	02/1998	WO 98/04740	WIPO			
OTHER DOCUMENTS <i>(including author, title, Date, Pertinent Pages, Etc.)</i>							
Examiner Initials	Ref. No.	Title					
93	2.	Bhatt et al., Nucleosides & Nucleotides (1999) 18(6&7):1297-1299					
↓	3.	Fritz et al., Journal of Colloid and Interface Science (1997) 195:272-288					
↓	4.	Lewis et al., Journal of Drug Targeting (1998) 5(4):291-302					
↓	5.	Schwab et al., Proc. Natl. Acad. Sci. USA (1994) 91:10460-10464					
EXAMINER: 93-				DATE CONSIDERED: 4-28-06			
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.							

Form PTO-1449

**INFORMATION DISCLOSURE CITATION
IN AN APPLICATION**

(Use several sheets if necessary)

Docket Number 377882001700

Application Number 09/802,376

Applicant

Gary VAN NEST et al.

Filing Date March 9, 2001

Group Art Unit 1635

Mailing Date September 20, 2004

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO

OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
93	1.	Busquets et al., <i>Current Drug Targets</i> (2003) 4:633-42.
	2.	Li et al., <i>Biochimica et Biophys Acta</i> (1993) 1166:145-53.
	3.	Fix et al., <i>FEBS Letters</i> (2002) 516:109-112.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.